Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Concert Pharmaceuticals revenue
Concert Pharmaceuticals's revenue is $32.6 million.
What is Concert Pharmaceuticals's revenue?
- Concert Pharmaceuticals's revenue growth from 2012 to 2021 is 153.55%.
- Concert Pharmaceuticals has 71 employees, and the revenue per employee ratio is $458,845.
- Concert Pharmaceuticals's peak quarterly revenue was $8.6B in 2014(q4).
- Concert Pharmaceuticals peak revenue was $8.6B in 2014.
- Concert Pharmaceuticals annual revenue for 2020 was 7.9M, 633.7% growth from 2019.
- Concert Pharmaceuticals annual revenue for 2021 was 32.6M, 312.28% growth from 2020.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Concert Pharmaceuticals historical revenue
Concert Pharmaceuticals's peak revenue was $8.6B in 2014. The peak quarterly revenue was $8.6B in 2014(q4).
Concert Pharmaceuticals's revenue increased from $12.8m in 2012 to $32.6M currently. That's a 153.55% change in annual revenue.
Concert Pharmaceuticals annual revenue
Concert Pharmaceuticals annual revenue over time
| Fiscal year / year | Concert Pharmaceuticals revenue |
|---|---|
| 2012 | $12.8M |
| 2013 | $25.4M |
| 2014 | $8.6B |
| 2015 | $66.7M |
| 2016 | $174,000 |
| 2017 | $143.9M |
| 2018 | $10.5M |
| 2019 | $1.1M |
| 2020 | $7.9M |
| 2021 | $32.6M |
Rate Concert Pharmaceuticals' financial transparency
Concert Pharmaceuticals annual growth
Concert Pharmaceuticals saw the greatest revenue growth in 2017, when revenue increased by 82,595.98%.
Concert Pharmaceuticals had the lowest revenue growth in 2016, when revenue changed by -99.74%.
Concert Pharmaceuticals annual growth rate over time
| Year | Concert Pharmaceuticals growth |
|---|---|
| 2013 | 98%↑ |
| 2014 | 33653%↑ |
| 2015 | -99%↓ |
| 2016 | -100%↓ |
| 2017 | 82596%↑ |
| 2018 | -93%↓ |
| 2019 | -90%↓ |
| 2020 | 634%↑ |
| 2021 | 312%↑ |
Concert Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Concert Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | - | - | $25.4M |
| 2014 | $1.6M | $1,235 | $4,418 | $8.6B |
| 2015 | $1.3M | $53.4M | $1.7M | $10.3M |
| 2016 | $56,000 | $71,000 | $26 | $173,847 |
| 2017 | $20 | $15 | $143,844 | $143.7M |
| 2018 | $10.5M | $2.0M | $11.0M | ($10.5B) |
| 2019 | $1.0B | $49 | $10 | $1.1M |
| 2020 | $7.0M | $6,387 | $1,501 | $7.9M |
| 2021 | $5,000 | $32.0M | $543,000 | $13,000 |
| 2022 | - | $21,000 | $8,000 | - |
Concert Pharmaceuticals jobs nearby
Do you work at Concert Pharmaceuticals?
Is Concert Pharmaceuticals transparent about its revenue structure?
Concert Pharmaceuticals financial information
| CEO | Roger D. Tung Ph.d |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 71 |
| Date Founded | 2006 |
| Headquarters | Lexington, Massachusetts |
| Number of Locations | 1 |
| Revenue | $32.6M |
| Net Income | -$80,051,000 |
| PE Ratio | -4.19 |
| Tax Rate | 0.0% |
| Market Capitalization | $335.7M |
| Total Assets | $165,316,000 |
| Ticker | CNCE |
Concert Pharmaceuticals jobs you might like
Concert Pharmaceuticals financing
Concert Pharmaceuticals received early financing of $10.0M on 2006-07-17.
| Series | Round size | Date |
|---|---|---|
| Series A | $10M | 07/2006 |
| Series B | $48.5M | 11/2006 |
| Series C | $37M | 04/2008 |
| Grant | $488K | 11/2010 |
| Series Unknown | $4M | 06/2011 |
| Post Ipo Debt | $30M | 06/2017 |
| Post Ipo Equity | $74.7M | 01/2020 |
Concert Pharmaceuticals investors
| Investors | Security type |
|---|---|
| QVT Financial | Series A |
| Skyline Ventures | Series A |
| TVM Capital Life Science | Series A |
| Three Arch Partners | Series A |
| Greylock Partners | Series A |
| Brookside Capital Inc | Series B |
| QVT Financial | Series B |
| Skyline Ventures | Series B |
| TVM Capital Life Science | Series B |
| Three Arch Partners | Series B |
| Flagship Pioneering Inc | Series B |
| Greylock Partners | Series B |
| New Leaf Venture Partners | Series B |
| Brookside Capital Inc | Series C |
| Westfield Capital Management | Series C |
| MEDIPHASE VENTURE PARTNERS | Series C |
| QVT Financial | Series C |
| Skyline Ventures | Series C |
| TVM Capital Life Science | Series C |
| Adage Capital Management | Series C |
| GSK PLC | Series C |
| Three Arch Partners | Series C |
| Flagship Pioneering Inc | Series C |
| Greylock Partners | Series C |
| New Leaf Venture Partners | Series C |
| GSK PLC | Series Unknown |
| HERCULES CAPITAL INC | Post Ipo Debt |
Concert Pharmaceuticals revenue FAQs
Search for jobs
Concert Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Concert Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Concert Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Concert Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Concert Pharmaceuticals. The data presented on this page does not represent the view of Concert Pharmaceuticals and its employees or that of Zippia.
Concert Pharmaceuticals may also be known as or be related to CONCERT PHARMACEUTICALS INC., Concert Pharmaceuticals, Concert Pharmaceuticals Inc and Concert Pharmaceuticals, Inc.